Nuwellis Earnings Call Balances Growth With Cash Strain

Nuwellis, Inc. ((NUWE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Nuwellis, Inc. struck a cautiously optimistic tone on its latest earnings call, pairing strong early commercial progress with a frank acknowledgment of financial strain. Management highlighted 26% revenue growth, rising margins, and strategic moves in pediatrics and kidney monitoring, but investors were reminded that losses, higher operating costs, and thin liquidity still weigh heavily on the story.

Revenue Growth and Scale

Nuwellis reported Q1 2026 revenue of $2.4 million, up 26% from $1.9 million a year earlier, driven largely by stronger console and circuit sales. While the growth rate is attractive, management conceded that the absolute scale remains modest relative to the company’s expense base and underscores its early-stage status.

Console and Circuit Momentum

The company sold 15 Aquadex consoles in the quarter, including upgrades, signaling solid demand for its fluid management platform. Circuit sales increased 15%, which management linked to a growing number of patients treated with Aquadex therapy and deeper utilization in existing accounts.

Gross Margin Improvement

Gross margin climbed to 70.1% in Q1 2026, representing about a 14% year-over-year improvement that materially enhances unit economics. The gain was attributed to better pricing discipline, a more favorable product mix, and the ongoing transition of manufacturing to contract partner KDI.

Pediatric Commercial Traction

Pediatrics has become a key growth engine, now accounting for roughly half of U.S. revenue as the company’s footprint expanded to 47 centers nationwide. Nuwellis highlighted console placements in six of the nation’s leading children’s hospitals, positioning pediatrics as a differentiated and validated market segment.

Strategic Acquisition and Product Expansion

The March 2026 acquisition of RendiaTech was framed as a major strategic step to extend Nuwellis’ cardiorenal platform into automated kidney function monitoring. Management said this capability will support more precise fluid removal and earlier kidney insight, broadening clinical value and cross-selling potential around its core therapy.

Intellectual Property and Clinical Leadership

The company secured a new U.S. patent tied to advanced safety design for pediatric extracorporeal therapy, supporting development of its Vivien pediatric CRRT system. Nuwellis also brought on Dr. Stuart Goldstein as director of clinical strategy, aiming to strengthen clinical evidence generation and guideline-level advocacy.

Leadership, Board, and Sales Force Strengthening

Nuwellis continued to rebuild its leadership bench by appointing Carisa Schultz as chief financial officer and adding industry veteran Martin Emerson to the board, while reappointing David McDonald. Three experienced sales leaders returned to the organization and a new South Texas territory was opened to support broader commercialization.

Capital Actions and Balance Sheet

To shore up liquidity, the company completed roughly a $5 million private placement and warrant inducement transaction during the period. As of March 31, 2026, Nuwellis reported approximately $2.2 million in cash and restricted cash with no debt, but management acknowledged that liquidity remains modest relative to current burn.

Operational Discipline and Burn Reduction Target

Management outlined a cash burn reduction plan aimed at cutting monthly burn by about 50% by Q4 2026 while concentrating spending on high-value commercial areas. The initiative is central to the investment case, with executives stressing tighter resource allocation and productivity as they push toward a more sustainable cost structure.

Net Loss and Rising Operating Expenses

Nuwellis posted a net loss attributable to common shareholders of about $4.3 million in Q1 2026, underscoring the gap between revenue and spending. Operating expenses climbed to roughly $6.0 million from $4.1 million a year earlier, a 46% increase driven by expanded sales headcount and higher compensation as the company leaned into growth.

Liquidity Constraints and Execution Risk

Despite the capital raise, Nuwellis’ approximately $2.2 million in cash and restricted cash at quarter-end highlights tight liquidity against its current loss run-rate. Management acknowledged that missing its burn reduction targets or seeing slower-than-expected commercial traction could heighten financing risk and pressure future strategic options.

RendiaTech Commercialization Timeline

Investors were reminded that the most valuable component of the RendiaTech deal, a bedside kidney-monitoring product, remains in development and is not yet on the U.S. market. Management is targeting a 2027 commercial introduction, implying that the full revenue and margin impact of the acquisition will phase in over multiple quarters.

Guidance and Forward-Looking View

Looking ahead, Nuwellis guided primarily around operational milestones rather than specific top-line targets, emphasizing a roughly 50% cut in monthly cash burn by Q4 2026. The company expects to sustain momentum in Aquadex adoption, deepen pediatric penetration, and bring the RendiaTech bedside kidney-monitoring product to the U.S. market in 2027 to build a more durable growth and margin profile.

Nuwellis’ latest earnings call offered a blend of encouraging commercial traction and sobering financial realities that will resonate with risk-tolerant investors. Execution on burn reduction, continued pediatric growth, and successful rollout of RendiaTech’s technology will be critical to turning early strategic wins into a more sustainable and scalable business model.